Error message

Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in _menu_load_objects() (line 568 of /var/www/development/merrimackXXX/site/includes/menu.inc).

Integrated.

Systems.

Solutions.

Thinking.

Merrimack is committed to the fight against cancer. We are a science-driven community seeking to understand the complexity of the disease, engineer better solutions and deliver life-saving results for patients.

MM-398 in combination with 5-fluorouracil and leucovorin demonstrates a statistically significant advantage in overall survival compared to the control arm, in patients with metastatic pancreatic cancer who have been previously treated with gemcitabine.

The Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval

Merrimack's Bad Idea Wins 2nd Annual Biotech Battle of the Bands

Merrimack was thrilled to participate in the 2nd Annual Battle of the Biotech Bands charity benefit event. The event raised over $60,000 and was attended by over 700 industry representatives. Merrimack’s BAD IDEA took top honors and awarded over $30,000 to our charity of choice - Dream Day on Cape Cod – a worthy cause serving families that have children with life-threatening illnesses or serious conditions. We thank everyone who made this event possible and look forward to participating again next year!

Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the United States and Taiwan. Merrimack retains commercialization rights in the United States. Under the terms of the agreement,Merrimack will receive a $100 million upfront payment from Baxter and is eligible to receive up to $870 million for additional milestone and royalty payments.

We believe the key
to achieving a deeper understanding of the complex and dynamic biology behind cancer requires a systems-based understanding of the interactions within a cancer cell and its surrounding environment. Our researchers apply systems biology as a tool to discover and develop better medicines.LEARN MORE

Systems theory addresses how individual parts interact as a whole and is used across a wide variety of fields such as engineering, physics, and meteorology. Merrimack utilizes some of the same tools to model complex biological systems and simulate how they function within the human body. LEARN MORE

Merrimack is currently using insights gained from our systems biology approach to develop diagnostics designed to help physicians identify which regimens will be best suited for each patient we treat. LEARN MORE

Merrimack currently has six therapeutic oncology candidates in clinical development, multiple product candidates in preclinical development, and an active Network Biology-driven discovery effort. LEARN MORE

Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies a systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development.